Latest Period
Q2 2026
Security Snapshot
BELITE BIO, INC - Ordinary shares, par value US$0.0001 per share (BLTE) Institutional Ownership
CUSIP: 07782B104
13F Institutional Holders and Ownership History from Q2 2022 to Q2 2026
Institutions Reporting
81
Shares (Excl. Options)
9,473,460
Price
$153.98
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary shares, par value US$0.0001 per share
- Symbol
- BLTE on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 9,473,460
- Total 13F value
- $1,441,536,647
- Portfolio coverage rank
- 0%
- Share change
- +332,333
- Value change
- +$49,400,038
- Number of holders
- 81
- Shares outstanding
- 40,449,516
- SEC-reported price per share
- $159.92
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- BLTE - BELITE BIO, INC - Ordinary shares, par value US$0.0001 per share is tracked under CUSIP 07782B104.
- 81 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 75 to 81 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,422,171,091 to $1,441,536,647.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 81 institutions filings for Q2 2026.
Security key
07782B104
Latest holder period
Q2 2026
13F holders
81
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
BLTE full holder history
BELITE BIO, INC SEC filings
BELITE BIO, INC company facts
BELITE BIO, INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 07782B104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
BLTE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Lin Bioscience International Ltd. | 54% | $1,065,034,885 | 17,095,263 | Lin Bioscience International Ltd. | 31 Dec 2024 | |||
| Darwin Global Management, Ltd. | 8.1% | +16% | $479,467,205 | +$65,024,200 | 3,027,704 | +16% | Darwin Global Management, Ltd. | 31 Dec 2025 |
| Lin Yu-Hsin | 3.1% | -57% | $212,905,624 | -$175,415,992 | 1,253,935 | -45% | Yu-Hsin Lin | 31 Mar 2026 |
As of 30 Jun 2026, 81 institutional investors reported holding 9,473,460 shares of BELITE BIO, INC - Ordinary shares, par value US$0.0001 per share (BLTE). This represents 23% of the company’s total 40,449,516 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
22%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Darwin Global Management, Ltd. | 7.6% | 3,077,219 | +0.65% | 12% | $456,588,244 |
| Paradigm Biocapital Advisors LP | 3% | 1,232,877 | +11% | 3.6% | $189,844,565 |
| RTW INVESTMENTS, LP | 1.8% | 715,332 | 0% | 0.94% | $110,150,398 |
| MILLENNIUM MANAGEMENT LLC | 1.2% | 494,564 | -13% | 0.05% | $76,155,438 |
| MAVERICK CAPITAL LTD | 0.98% | 396,311 | 0.55% | $61,025,949 | |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.97% | 390,829 | +9.3% | 0.8% | $60,181,804 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 0.88% | 357,199 | +17% | 0.57% | $55,003,288 |
| Holocene Advisors, LP | 0.62% | 251,035 | -49% | 0.09% | $38,655,624 |
| Logos Global Management LP | 0.62% | 250,000 | 1.7% | $38,496,250 | |
| MORGAN STANLEY | 0.58% | 235,071 | +17% | 0% | $36,197,407 |
| UBS Group AG | 0.56% | 224,989 | -71% | 0.01% | $34,644,931 |
| CITADEL ADVISORS LLC | 0.46% | 186,168 | +9171% | 0.02% | $28,667,080 |
| GOLDMAN SACHS GROUP INC | 0.41% | 166,188 | +58% | 0% | $25,590,459 |
| Affinity Asset Advisors, LLC | 0.41% | 165,000 | +154% | 1.2% | $25,407,525 |
| MPM BIOIMPACT LLC | 0.34% | 137,208 | +56% | 1.3% | $21,127,974 |
| BANK OF AMERICA CORP /DE/ | 0.31% | 124,783 | +3203% | 0% | $19,214,710 |
| Patient Square Capital LP | 0.27% | 110,000 | -5.7% | 2.6% | $16,938,350 |
| Duquesne Family Office LLC | 0.26% | 106,100 | 0% | 0.38% | $16,338,000 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.26% | 105,859 | -62% | 0% | $16,301,000 |
| JANE STREET GROUP, LLC | 0.16% | 65,801 | +438% | 0.01% | $10,132,367 |
| BNP PARIBAS FINANCIAL MARKETS | 0.14% | 57,125 | 0% | 0% | $8,796,393 |
| RENAISSANCE TECHNOLOGIES LLC | 0.14% | 55,763 | +7.2% | 0.01% | $8,586,666 |
| Point72 Asset Management, L.P. | 0.13% | 51,186 | 0.01% | $7,881,877 | |
| Soleus Capital Management, L.P. | 0.12% | 50,524 | 0.27% | $7,779,938 | |
| Trexquant Investment LP | 0.12% | 49,516 | +229% | 0.05% | $7,624,721 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
17
Latest
Q2 2026
Rows shown
1-17 of 17
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 9,473,460 | $1,441,536,647 | +$49,400,038 | $153.98 | 81 |
| 2026 Q1 | 9,116,527 | $1,422,171,091 | +$301,669,955 | $159.44 | 75 |
| 2025 Q4 | 7,191,642 | $1,153,000,250 | +$810,023,763 | $159.96 | 70 |
| 2025 Q3 | 2,288,469 | $169,346,585 | +$162,953,207 | $74.00 | 34 |
| 2025 Q2 | 78,139 | $4,508,619 | -$5,101,966 | $57.70 | 18 |
| 2025 Q1 | 149,657 | $9,909,658 | -$8,038,751 | $66.22 | 18 |
| 2024 Q4 | 282,406 | $17,820,740 | +$12,809,959 | $63.10 | 21 |
| 2024 Q3 | 78,699 | $3,689,407 | -$4,872,726 | $46.88 | 15 |
| 2024 Q2 | 186,568 | $8,522,342 | +$5,980,161 | $45.68 | 11 |
| 2024 Q1 | 58,112 | $2,229,758 | -$4,083,463 | $38.37 | 11 |
| 2023 Q4 | 155,109 | $7,095,600 | +$3,531,143 | $45.75 | 17 |
| 2023 Q3 | 99,593 | $3,165,868 | -$26,250,075 | $31.85 | 7 |
| 2023 Q2 | 1,040,502 | $14,866,363 | +$2,374,158 | $14.29 | 6 |
| 2023 Q1 | 850,185 | $25,389,513 | -$211,069 | $29.90 | 8 |
| 2022 Q4 | 857,329 | $25,861,711 | +$22,306,675 | $30.15 | 7 |
| 2022 Q3 | 115,088 | $3,870,578 | +$1,586,624 | $33.76 | 8 |
| 2022 Q2 | 68,935 | $2,146,000 | +$2,146,000 | $31.13 | 6 |